Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.

In an essay for 'Women's Health,' Dr. Nora Volkow discusses the future of semaglutide weight-loss meds, and their potential ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief executive officer Michele Buck told analysts in a conference call on fiscal 2024 ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Provides longer GLP-1 receptor activation. Depending on the medication, the effects can last for a minimum of 24 hours to a ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

For example, a starter dose of Novo’s Ozempic is 25 milligrams ... Hims' business has grown significantly, as have other ...

This is just a glimpse of the GLP-1 insights available to CivicScience clients. Want to see the full picture? Let’s talk.